Catalent Inc

CTLT

Equity

ISIN US1488061029 / Valor 23576319

New York Stock Exchange, Inc (2024-11-21)

USD 59.66+1.12%

Catalent Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Catalent Inc. is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for the pharmaceutical, biotechnology, and consumer health industries. As a Contract Development and Manufacturing Organization (CDMO), Catalent plays a crucial role in the lifecycle of medical and health products by offering a broad range of services. These services include the development of drug formulations, biologic and biosimilar development, clinical trial solutions, and the manufacturing and packaging of drugs in various dosage forms. The company's expertise in improving drug delivery mechanisms and its comprehensive supply chain solutions make it a vital partner for innovators looking to bring superior health products to market. Catalent's commitment to enhancing patient care through its services underscores its position as a key player in the health care sector, aiming to accelerate the availability of medical advancements globally.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Catalent Inc. reported net revenue of $1.07 billion for the third quarter of fiscal 2024, which represents a 4% increase as reported, or 3% in constant currency, compared to the same quarter in the previous year. Excluding COVID-related revenue, the net revenue increased by 11% year-over-year.

Net Loss Reduction

For the third quarter of fiscal 2024, Catalent Inc. reported a net loss of $(101) million, a significant improvement compared to the net loss of $(227) million in the third quarter of fiscal 2023. This reduction in net loss highlights the company's efforts to improve its financial performance.

Adjusted EBITDA Increase

Catalent Inc. achieved an Adjusted EBITDA of $163 million in the third quarter of fiscal 2024, marking a 55% increase as reported, or 53% in constant currency, compared to the same period in the previous year. This improvement reflects the company's enhanced operational efficiency and profitability.

Segment Performance

In the third quarter of fiscal 2024, Catalent Inc.'s Biologics segment reported net revenue of $461 million, a 3% decrease from the previous year, but saw a significant increase in Segment EBITDA by 876%. The Pharma and Consumer Health segment reported an 8% increase in net revenue to $613 million and a 21% increase in Segment EBITDA.

Balance Sheet and Liquidity

As of March 31, 2024, Catalent Inc. had total debt of $4.98 billion and total available liquidity of approximately $1.3 billion. The company's net leverage ratio improved to 9.3x, down from 10.3x at the end of the previous quarter, indicating better financial stability and reduced leverage.

Summarized from source with an LLMView Source

Key figures

49.7%1Y

-53.1%3Y

15.7%5Y

Performance

25.8%1Y

52.1%3Y

48.5%5Y

Volatility